Addressing Theoretical and Practical Limitations of Characterizing and Treating ‘Treatment Resistant’ Schizophrenia

BibBase https://api.zotero.org/users/6447874/collections/AWT385HL/items?key=H3htGET3wpaMkrtfDpenhbtf&format=bibtex&limit=100
generated by bibbase.org
  2022 (11)
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Spark, D. L.; Fornito, A.; Langmead, C. J.; and Stewart, G. D. Translational Psychiatry, 12(1): 1–11. April 2022. Number: 1 Publisher: Nature Publishing Group
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics [link]Paper   doi   link   bibtex   abstract  
MDMA for the Treatment of Negative Symptoms in Schizophrenia. Arnovitz, M. D.; Spitzberg, A. J.; Davani, A. J.; Vadhan, N. P.; Holland, J.; Kane, J. M.; and Michaels, T. I. Journal of Clinical Medicine, 11(12): 3255. January 2022. Number: 12 Publisher: Multidisciplinary Digital Publishing Institute
MDMA for the Treatment of Negative Symptoms in Schizophrenia [link]Paper   doi   link   bibtex   abstract  
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics. Spark, D. L.; Fornito, A.; Langmead, C. J.; and Stewart, G. D. Translational Psychiatry, 12(1): 1–11. April 2022. Number: 1 Publisher: Nature Publishing Group
Beyond antipsychotics: a twenty-first century update for preclinical development of schizophrenia therapeutics [link]Paper   doi   link   bibtex   abstract  
Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities. Nair, P. C.; Chalker, J. M.; McKinnon, R. A.; Langmead, C. J; Gregory, K. J.; and Bastiampillai, T. ACS Pharmacology & Translational Science, 5(3): 183–188. March 2022. Publisher: American Chemical Society
Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities [link]Paper   doi   link   bibtex   abstract  
In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia. Xiao, G.; Chen, Y.; Dedic, N.; Xie, L.; Koblan, K. S.; and Galluppi, G. R. Pharmaceutical Research, 39(5): 837–850. May 2022.
doi   link   bibtex   abstract  
Candidates for Drug Repurposing to Address the Cognitive Symptoms in Schizophrenia. Koch, E.; Kauppi, K.; and Chen, C. Technical Report Genetics, March 2022.
Candidates for Drug Repurposing to Address the Cognitive Symptoms in Schizophrenia [link]Paper   doi   link   bibtex   abstract  
Drug Discovery Paradigms: Phenotypic-Based Drug Discovery. Talevi, A.; and Bellera, C. L. In Scotti, M. T.; and Bellera, C. L., editor(s), Drug Target Selection and Validation, of Computer-Aided Drug Discovery and Design, pages 25–40. Springer International Publishing, Cham, 2022.
Drug Discovery Paradigms: Phenotypic-Based Drug Discovery [link]Paper   doi   link   bibtex   abstract  
The doors of precision: Reenergizing psychiatric drug development with psychedelics and open access computational tools. Barron, D. S.; and Friedman, R. A. Science Advances, 8(11): eabp8283. March 2022.
The doors of precision: Reenergizing psychiatric drug development with psychedelics and open access computational tools [link]Paper   doi   link   bibtex   abstract  
The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets. Lago, S. G.; and Bahn, S. npj Genomic Medicine, 7(1): 1–13. March 2022. Number: 1 Publisher: Nature Publishing Group
The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets [link]Paper   doi   link   bibtex   abstract  
The doors of precision: Reenergizing psychiatric drug development with psychedelics and open access computational tools. Barron, D. S.; and Friedman, R. A. Science Advances, 8(11): eabp8283. March 2022.
The doors of precision: Reenergizing psychiatric drug development with psychedelics and open access computational tools [link]Paper   doi   link   bibtex   abstract  
Two large studies reveal genes and genome regions that influence schizophrenia risk. April 2022. Section: Research News
Two large studies reveal genes and genome regions that influence schizophrenia risk [link]Paper   link   bibtex   abstract  
  2021 (14)
The Promise of Psychedelic Science. Olson, D. E. ACS Pharmacology & Translational Science, 4(2): 413–415. April 2021. Publisher: American Chemical Society
The Promise of Psychedelic Science [link]Paper   doi   link   bibtex  
Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review. Alnefeesi, Y.; Tamura, J. K.; Lui, L. M. W.; Jawad, M. Y.; Ceban, F.; Ling, S.; Nasri, F.; Rosenblat, J. D.; and McIntyre, R. S. Neuroscience & Biobehavioral Reviews, 131: 192–210. December 2021.
Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review [link]Paper   doi   link   bibtex   abstract  
Beyond Dopamine Receptor Antagonism: New Targets for Schizophrenia Treatment and Prevention. Gomes, F. V.; and Grace, A. A. International Journal of Molecular Sciences, 22(9): 4467. April 2021.
doi   link   bibtex   abstract  
An Early Stage Researcher's Primer on Systems Medicine Terminology. Zanin, M.; Aitya, N. A.; Basilio, J.; Baumbach, J.; Benis, A.; Behera, C. K.; Bucholc, M.; Castiglione, F.; Chouvarda, I.; Comte, B.; Dao, T.; Ding, X.; Pujos-Guillot, E.; Filipovic, N.; Finn, D. P.; Glass, D. H.; Harel, N.; Iesmantas, T.; Ivanoska, I.; Joshi, A.; Boudjeltia, K. Z.; Kaoui, B.; Kaur, D.; Maguire, L. P.; McClean, P. L.; McCombe, N.; de Miranda, J. L.; Moisescu, M. A.; Pappalardo, F.; Polster, A.; Prasad, G.; Rozman, D.; Sacala, I.; Sanchez-Bornot, J. M.; Schmid, J. A.; Sharp, T.; Solé-Casals, J.; Spiwok, V.; Spyrou, G. M.; Stalidzans, E.; Stres, B.; Sustersic, T.; Symeonidis, I.; Tieri, P.; Todd, S.; Van Steen, K.; Veneva, M.; Wang, D.; Wang, H.; Wang, H.; Watterson, S.; Wong-Lin, K.; Yang, S.; Zou, X.; and Schmidt, H. H. Network and Systems Medicine, 4(1): 2–50. March 2021. Publisher: Mary Ann Liebert, Inc., publishers
An Early Stage Researcher's Primer on Systems Medicine Terminology [link]Paper   doi   link   bibtex   abstract  
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. Lam, M.; Chen, C.; Ge, T.; Xia, Y.; Hill, D. W.; Trampush, J. W.; Yu, J.; Knowles, E.; Davies, G.; Stahl, E. A.; Huckins, L.; Liewald, D. C.; Djurovic, S.; Melle, I.; Christoforou, A.; Reinvang, I.; DeRosse, P.; Lundervold, A. J.; Steen, V. M.; Espeseth, T.; Räikkönen, K.; Widen, E.; Palotie, A.; Eriksson, J. G.; Giegling, I.; Konte, B.; Hartmann, A. M.; Roussos, P.; Giakoumaki, S.; Burdick, K. E.; Payton, A.; Ollier, W.; Chiba-Falek, O.; Koltai, D. C.; Need, A. C.; Cirulli, E. T.; Voineskos, A. N.; Stefanis, N. C.; Avramopoulos, D.; Hatzimanolis, A.; Smyrnis, N.; Bilder, R. M.; Freimer, N. B.; Cannon, T. D.; London, E.; Poldrack, R. A.; Sabb, F. W.; Congdon, E.; Conley, E. D.; Scult, M. A.; Dickinson, D.; Straub, R. E.; Donohoe, G.; Morris, D.; Corvin, A.; Gill, M.; Hariri, A. R.; Weinberger, D. R.; Pendleton, N.; Bitsios, P.; Rujescu, D.; Lahti, J.; Le Hellard, S.; Keller, M. C.; Andreassen, O. A.; Deary, I. J.; Glahn, D. C.; Huang, H.; Liu, C.; Malhotra, A. K.; and Lencz, T. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 46(10): 1788–1801. September 2021.
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. [link]Paper   doi   link   bibtex   abstract  
An Early Stage Researcher's Primer on Systems Medicine Terminology. Zanin, M.; Aitya, N. A.; Basilio, J.; Baumbach, J.; Benis, A.; Behera, C. K.; Bucholc, M.; Castiglione, F.; Chouvarda, I.; Comte, B.; Dao, T.; Ding, X.; Pujos-Guillot, E.; Filipovic, N.; Finn, D. P.; Glass, D. H.; Harel, N.; Iesmantas, T.; Ivanoska, I.; Joshi, A.; Boudjeltia, K. Z.; Kaoui, B.; Kaur, D.; Maguire, L. P.; McClean, P. L.; McCombe, N.; de Miranda, J. L.; Moisescu, M. A.; Pappalardo, F.; Polster, A.; Prasad, G.; Rozman, D.; Sacala, I.; Sanchez-Bornot, J. M.; Schmid, J. A.; Sharp, T.; Solé-Casals, J.; Spiwok, V.; Spyrou, G. M.; Stalidzans, E.; Stres, B.; Sustersic, T.; Symeonidis, I.; Tieri, P.; Todd, S.; Van Steen, K.; Veneva, M.; Wang, D.; Wang, H.; Wang, H.; Watterson, S.; Wong-Lin, K.; Yang, S.; Zou, X.; and Schmidt, H. H. Network and Systems Medicine, 4(1): 2–50. March 2021. Publisher: Mary Ann Liebert, Inc., publishers
An Early Stage Researcher's Primer on Systems Medicine Terminology [link]Paper   doi   link   bibtex   abstract  
Signature-based approaches for informed drug repurposing: targeting CNS disorders. Shukla, R.; Henkel, N. D.; Alganem, K.; Hamoud, A.; Reigle, J.; Alnafisah, R. S.; Eby, H. M.; Imami, A. S.; Creeden, J. F; Miruzzi, S. A.; Meller, J.; and Mccullumsmith, R. E. Neuropsychopharmacology, 46(1): 116–130. January 2021.
Signature-based approaches for informed drug repurposing: targeting CNS disorders [link]Paper   doi   link   bibtex   abstract  
Signature-based approaches for informed drug repurposing: targeting CNS disorders. Shukla, R.; Henkel, N. D.; Alganem, K.; Hamoud, A.; Reigle, J.; Alnafisah, R. S.; Eby, H. M.; Imami, A. S.; Creeden, J. F; Miruzzi, S. A.; Meller, J.; and Mccullumsmith, R. E. Neuropsychopharmacology, 46(1): 116–130. January 2021.
Signature-based approaches for informed drug repurposing: targeting CNS disorders [link]Paper   doi   link   bibtex   abstract  
In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis. Mejia-Gutierrez, M.; Vásquez-Paz, B. D.; Fierro, L.; and Maza, J. R. ACS Omega, 6(23): 14748–14764. June 2021. Publisher: American Chemical Society
In Silico Repositioning of Dopamine Modulators with Possible Application to Schizophrenia: Pharmacophore Mapping, Molecular Docking and Molecular Dynamics Analysis [link]Paper   doi   link   bibtex   abstract  
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. Lam, M.; Chen, C.; Ge, T.; Xia, Y.; Hill, D. W.; Trampush, J. W.; Yu, J.; Knowles, E.; Davies, G.; Stahl, E. A.; Huckins, L.; Liewald, D. C.; Djurovic, S.; Melle, I.; Christoforou, A.; Reinvang, I.; DeRosse, P.; Lundervold, A. J.; Steen, V. M.; Espeseth, T.; Räikkönen, K.; Widen, E.; Palotie, A.; Eriksson, J. G.; Giegling, I.; Konte, B.; Hartmann, A. M.; Roussos, P.; Giakoumaki, S.; Burdick, K. E.; Payton, A.; Ollier, W.; Chiba-Falek, O.; Koltai, D. C.; Need, A. C.; Cirulli, E. T.; Voineskos, A. N.; Stefanis, N. C.; Avramopoulos, D.; Hatzimanolis, A.; Smyrnis, N.; Bilder, R. M.; Freimer, N. B.; Cannon, T. D.; London, E.; Poldrack, R. A.; Sabb, F. W.; Congdon, E.; Conley, E. D.; Scult, M. A.; Dickinson, D.; Straub, R. E.; Donohoe, G.; Morris, D.; Corvin, A.; Gill, M.; Hariri, A. R.; Weinberger, D. R.; Pendleton, N.; Bitsios, P.; Rujescu, D.; Lahti, J.; Le Hellard, S.; Keller, M. C.; Andreassen, O. A.; Deary, I. J.; Glahn, D. C.; Huang, H.; Liu, C.; Malhotra, A. K.; and Lencz, T. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 46(10): 1788–1801. September 2021.
Identifying nootropic drug targets via large-scale cognitive GWAS and transcriptomics. [link]Paper   doi   link   bibtex   abstract  
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia. Heffernan, M. L. R.; Herman, L. W.; Brown, S.; Jones, P. G.; Shao, L.; Hewitt, M. C.; Campbell, J. E.; Dedic, N.; Hopkins, S. C.; Koblan, K. S.; and Xie, L. ACS Medicinal Chemistry Letters. December 2021. Publisher: American Chemical Society
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia [link]Paper   doi   link   bibtex   abstract  
Amphetamines signal through intracellular TAAR1 receptors coupled to Gα13 and GαS in discrete subcellular domains. Underhill, S. M.; Hullihen, P. D.; Chen, J.; Fenollar-Ferrer, C.; Rizzo, M. A.; Ingram, S. L.; and Amara, S. G. Molecular Psychiatry, 26(4): 1208–1223. April 2021. Bandiera_abtest: a Cc_license_type: cc_by Cg_type: Nature Research Journals Number: 4 Primary_atype: Research Publisher: Nature Publishing Group Subject_term: Cell biology;Neuroscience Subject_term_id: cell-biology;neuroscience
Amphetamines signal through intracellular TAAR1 receptors coupled to Gα13 and GαS in discrete subcellular domains [link]Paper   doi   link   bibtex   abstract  
Quantitative systems pharmacology in neuroscience: Novel methodologies and technologies. Bloomingdale, P.; Karelina, T.; Cirit, M.; Muldoon, S. F.; Baker, J.; McCarty, W. J.; Geerts, H.; and Macha, S. CPT: Pharmacometrics & Systems Pharmacology, 10(5): 412–419. 2021. _eprint: https://onlinelibrary.wiley.com/doi/pdf/10.1002/psp4.12607
Quantitative systems pharmacology in neuroscience: Novel methodologies and technologies [link]Paper   doi   link   bibtex   abstract  
Optogenetics and Controlling the Human Mind. Guynn, M. Curiosity: Interdisciplinary Journal of Research and Innovation,28096. September 2021. Publisher: Dixie State University
Optogenetics and Controlling the Human Mind [link]Paper   doi   link   bibtex   abstract  
  2020 (3)
TAAR Agonists. Xu, Z.; and Li, Q. Cellular and Molecular Neurobiology, 40(2): 257–272. March 2020.
doi   link   bibtex   abstract  
Molecular Variants in Human Trace Amine-Associated Receptors and Their Implications in Mental and Metabolic Disorders. Rutigliano, G.; and Zucchi, R. Cellular and Molecular Neurobiology, 40(2): 239–255. March 2020.
Molecular Variants in Human Trace Amine-Associated Receptors and Their Implications in Mental and Metabolic Disorders [link]Paper   doi   link   bibtex   abstract  
Exome sequencing identifies rare coding variants in 10 genes which confer substantial risk for schizophrenia. Singh, T.; Neale, B. M.; Daly, M. J.; and Consortium, o. b. o. t. S. E. M. (. Technical Report medRxiv, September 2020. Type: article
Exome sequencing identifies rare coding variants in 10 genes which confer substantial risk for schizophrenia [link]Paper   doi   link   bibtex   abstract  
  2019 (2)
Hallucinations and Strong Priors. Corlett, P. R.; Horga, G.; Fletcher, P. C.; Alderson-Day, B.; Schmack, K.; and Powers, A. R. Trends in Cognitive Sciences, 23(2): 114–127. February 2019.
doi   link   bibtex   abstract  
Schizophrenia. Marder, S. R.; and Cannon, T. D. New England Journal of Medicine, 381(18): 1753–1761. October 2019.
Schizophrenia [link]Paper   doi   link   bibtex  
  2017 (1)
What Can Different Motor Circuits Tell Us About Psychosis? An RDoC Perspective. Mittal, V. A; Bernard, J. A; and Northoff, G. Schizophrenia Bulletin, 43(5): 949–955. September 2017.
What Can Different Motor Circuits Tell Us About Psychosis? An RDoC Perspective [link]Paper   doi   link   bibtex   abstract  
  2016 (2)
BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology. Gilson, M. K.; Liu, T.; Baitaluk, M.; Nicola, G.; Hwang, L.; and Chong, J. Nucleic Acids Research, 44(D1): D1045–1053. January 2016.
doi   link   bibtex   abstract  
Maternal immune activation: Implications for neuropsychiatric disorders. Estes, M. L.; and McAllister, A. K. Science, 353(6301): 772–777. August 2016.
Maternal immune activation: Implications for neuropsychiatric disorders [link]Paper   doi   link   bibtex   abstract  
  2001 (1)
Trace amines: Identification of a family of mammalian G protein-coupled receptors. Borowsky, B.; Adham, N.; Jones, K. A.; Raddatz, R.; Artymyshyn, R.; Ogozalek, K. L.; Durkin, M. M.; Lakhlani, P. P.; Bonini, J. A.; Pathirana, S.; Boyle, N.; Pu, X.; Kouranova, E.; Lichtblau, H.; Ochoa, F. Y.; Branchek, T. A.; and Gerald, C. Proceedings of the National Academy of Sciences, 98(16): 8966–8971. July 2001. Publisher: Proceedings of the National Academy of Sciences
Trace amines: Identification of a family of mammalian G protein-coupled receptors [link]Paper   doi   link   bibtex  
  undefined (8)
Manual \textbar ApiNATOMY Lyph Viewer.
Manual \textbar ApiNATOMY Lyph Viewer [link]Paper   link   bibtex  
Inflammatory bowel disease-associated gene set projecte \textbar Open-i.
Inflammatory bowel disease-associated gene set projecte \textbar Open-i [link]Paper   link   bibtex  
Impact of GPCR Structures on Drug Discovery - ScienceDirect.
Impact of GPCR Structures on Drug Discovery - ScienceDirect [link]Paper   link   bibtex  
Actions of Trace Amines in the Brain-Gut-Microbiome Axis via Trace Amine-Associated Receptor-1 (TAAR1). Bugda Gwilt, K.; González, D. P.; Olliffe, N.; Oller, H.; Hoffing, R.; Puzan, M.; El Aidy, S.; and Miller, G. M. Cellular and Molecular Neurobiology, 40(2): 191–201. .
doi   link   bibtex   abstract  
Redefining the standard of care for brain disorders \textbar MapLight Therapeutics.
Redefining the standard of care for brain disorders \textbar MapLight Therapeutics [link]Paper   link   bibtex   abstract  
Candidates for Drug Repurposing to Address the Cognitive Symptoms in Schizophrenia \textbar bioRxiv.
Candidates for Drug Repurposing to Address the Cognitive Symptoms in Schizophrenia \textbar bioRxiv [link]Paper   link   bibtex  
Results \textbar SCHEMA browser.
Results \textbar SCHEMA browser [link]Paper   link   bibtex  
Experimental schizophrenia drug could reduce long-neglected symptoms.
Experimental schizophrenia drug could reduce long-neglected symptoms [link]Paper   link   bibtex   abstract  

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

butwhatdoweknow.com is licensed under Attribution-ShareAlike 4.0 International

error: Content is protected !!